Amphia Hospital — Clinical Trial Site

188 Registered trials

64 Currently recruiting

Organisation

Amphia Hospital

Location

Breda, Netherlands

Identifier

ORG-100029470

Address

Molengracht 21, 4818 CK, Netherlands

Departments

#40351: Dermatology
#5004:Dermatology
031003: Pediatrics
2601:Cardiology
4901:Pulmonology
5002: Lung Disease and Tuberculosis
5003: Cardiology
93142001: Int.Geneeskunde - Oncologie
98342001: Medical Oncology
Afd. Interne Geneeskunde
Afdeling Oncologie / Interne Geneeskunde
Amphia
Amphia Hospital
Amphia Ziekenhuis Molengracht( #2)
Amphia Ziekenhuis, Molengracht
Amphia Ziekenhuis, Molengracht (#1)
Anaesthesia
Anesthesiology
Anesthesiology and palliative care
Cardiologie
Cardiology
Clinical Pharmacy
Department of Haematology
Department of Hematology
Department of Hospital Pharmacy
Department of medical oncology
Department of Neurology
Department of Pulmonary Diseases
Department of pulmonary diseases and center for sleep medicine
Department of Pulmonology
Department of Surgery
Dept Opthalmology
Dept Pulmonary Diseases
Dermatologie
Dermatology
Endocrinologie
Gynaecology
Gynecology and obstetrics
Haematology
Hematologie
Hematology
ICU
Intensive Care
Internal Medicine
Internal Medicine - Hematology
Internal medicine – oncology hematology
Interne Geneeskunde
Interne geneeskunde/oncologie
Internist Hematology
Interventional Cardiology
Kindergeneeskunde
Long Oncologie
Longgeneeskunde
Longoncologie
Lung department
Lung Diseases
Lungdiseases (Long afdeling)
MDL
Medical Oncology
Medische Oncologie
N/A
NA
Nephrology
Neruology
Neurology
NL10011: Int.Geneeskunde - Oncologie
Obstetrics & Gynecology
Oncologie
Oncology
Oncology Center: Breast Cancer
Orthopedic Surgery
Paediatric Gastroenterology
Pediatrics
Pneumology
Pulmonary medicine
Pulmonary Science
Pulmonology
Pulmonology department
Reproductive medicine and gynecology
Research Cardiology
Rheumatology
Surgery
Urology
Vakgroep Maag-, Darm- en Leverziekten

Clinical trials at this site (188)

Search interface

A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Ended

2022-502324-48-00 Patients with resected colon carcinoma 5 2014-08-05
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-lin… Ended

2024-516202-39-00 Metastatic breast cancer 4 2013-10-10
PUMP-IT RCT: Hepatic arterial infusion PUMP chemotherapy combined with systemic therapy versus systemic therapy alone as Induction Therapy f… Halted

2023-506194-35-00 Colorectal liver metastases 5 2024-11-21
Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta… Halted

2024-511708-18-00 Locally advanced or metastatic KRAS G12C-mutated non-sm 4 2022-12-06
THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDE… Ended

2024-516260-29-00 non-metastatic (borderline) resectable pancreatic cance 5 2024-10-10
A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis Ended

2023-510249-79-00 Progressive pulmonary fibrosis (PPF) 4 2024-09-10
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Modera… Ended

2023-505433-27-00 Atopic Dermatitis 5 2024-08-13
A Phase IIb Two-Cohort, Randomised, Placebo controlled, Double blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients with Ch… Ended

2023-510148-19-00 Chronic Heart Failure 4 2024-07-03
A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr… Ended

2023-508663-70-00 Bronchiectasis 4 2024-06-18
A study on the immune response and safety of a vaccine against respiratory syncytial virus (RSV) when given alone and together with a vaccin… Ended

2023-510196-59-00 Respiratory Syncytial Virus Infections 5 2024-06-15
A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherap… Ended

2022-502653-34-01 Atopic dermatitis and moderate-to severe atopic hand ec 11 2024-05-30
A study to learn about how elinzanetant works and how safe it is in women having sleep disturbances associated with menopause Ended

2023-504955-28-01 Sleep disturbances associated with menopause 4 2024-03-14
Functional Constipation: Linaclotide versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, with Functional Constipation (FC) Ended

2022-501946-31-00 Functional Constipation 5 2024-02-29
"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended

2023-505543-39-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-02-12
A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p… Ended

2023-503333-22-00 Moderate to severe controlled asthma according to Step 5 2024-01-15
A study to test the efficacy and safety of SAR442970 in adults with hidradenitis suppurativa Ended

2022-502370-17-00 Hidradenitis suppurativa 4 2023-11-14
A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV … Ended

2022-502620-49-00 Resected Melanoma Stage III or Stage IV 2 2023-08-01
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501752-29-00 Hidradenitis Suppurativa 5 2023-06-15
MERCURI-2 Ended

2024-515260-31-00 AKI 6 2023-06-09
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-504869-23-00 Dermatitis atopic 11 2023-05-31
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel… Ended

2023-509243-27-00 Moderate-to-Severe Uncontrolled Asthma 4 2023-04-12
A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)] Ended

2022-501426-38-00 Lipoprotein Disorder 4 2023-02-09
The effect of oral folinic acid to prevent pemetrexed induced adverse events. Ended

2022-502345-10-00 Non small cell lung cancer (NSCLC), Mesothelioma, Thymo 6 2023-02-05